Although anecdotal data on IL6 inhibitors (e.g. anti-IL6R antibody Tocilizumab) in pregnant women with inflammatory disorders such as rheumatoid arthritis or severe COVID-19 during pregnancy are reported (53), systematic studies of safety and efficacy have not been reported thus far. This evidence concerns the gene IL6 and COVID-19.